Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyronaridine-artesunate for COVID-19 and Malaria Co-infection
NCT04695197Phase 3Completed
- Sponsor
- Liverpool School of Tropical Medicine
- Start
- Jan 2021
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of artesunate + pyronaridine in coronavirus disease 2019 (COVID-19) and malaria (2 arms), sponsored by Liverpool School of Tropical Medicine. Primary endpoint: Incidence of SARS-CoV-2 clearance at Day 7. Started Jan 2021; status: completed.
02
Drugs
artesunate + pyronaridine
03
Conditions
coronavirus disease 2019 (COVID-19)malaria
Beyond the preview
Go deeper on NCT04695197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04695197.